Journal
JOURNAL OF NUCLEAR MEDICINE
Volume 59, Issue 1, Pages 89-92Publisher
SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.117.192625
Keywords
PSMA; PET/CT; prostate cancer; biochemical recurrence; management change
Funding
- UCLH NIHR BRC
- UCL Experimental Cancer Medicine Centre
- London North West Healthcare Charitable Fund
- UCLH/UCL Comprehensive Biomedical Research Centre
- MRC [G0701302, G1002509] Funding Source: UKRI
- Cancer Research UK [16463] Funding Source: researchfish
- Medical Research Council [G0701302, G1002509] Funding Source: researchfish
- National Institute for Health Research [CL-2007-18-015] Funding Source: researchfish
- Prostate Cancer UK [PG13-025] Funding Source: researchfish
Ask authors/readers for more resources
The objective of this study was to assess the impact of Ga-68-prostate-specific membrane antigen (Ga-68-PSMA) PET/CT on the management of prostate cancer in patients with biochemical recurrence (BCR). Methods: Documented management plans before and after Ga-68-PSMA PET/CT in 100 patients with BCR were retrospectively reviewed, and changes in plans were recorded. Results: Management changed after Ga-68-PSMA PET/CT in 39 patients (39%). The management changes occurred in 23 (33.8%) of 68 patients with radical prostatectomy and 16 (50%) of 32 patients previously treated with radical radiotherapy. Positive scan results (P < 0.001) and higher prostate-specific antigen (PSA) levels (P = 0.024) were associated with management changes. No significant association with management change was found for Gleason grade, stage, presence of metastatic disease, PSA velocity, or PSA doubling time. Conclusion: Ga-68-PSMA PET/CT altered management in 39% of patients with BCR, and changes occurred more often in patients with radical radiotherapy treatment, positive Ga-68-PSMA scan results, and higher PSA levels.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available